Wells Fargo
ORIC icon

Wells Fargo’s Oric Pharmaceuticals ORIC Stock Holding History

Wells Fargo’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$942K Buy
87,009
+47,901
+122% +$434K ﹤0.01% 4153
2026
Q1 		$495K Sell
39,108
-43,424
-53% -$493K ﹤0.01% 4179
2025
Q4 		$675K Buy
82,532
+31,569
+62% +$363K ﹤0.01% 4250
2025
Q3 		$612K Buy
50,963
+17,360
+52% +$183K ﹤0.01% 4150
2025
Q2 		$341K Sell
33,603
-5,385
-14% -$36.2K ﹤0.01% 4411
2025
Q1 		$218K Buy
38,988
+3,131
+9% +$27.4K ﹤0.01% 4646
2024
Q4 		$289K Buy
35,857
+8,311
+30% +$76.3K ﹤0.01% 4557
2024
Q3 		$282K Buy
27,546
+767
+3% +$7.58K ﹤0.01% 4352
2024
Q2 		$189K Buy
26,779
+11,562
+76% +$103K ﹤0.01% 4548
2024
Q1 		$209K Buy
15,217
+1,786
+13% +$21.2K ﹤0.01% 4442
2023
Q4 		$124K Buy
13,431
+2,122
+19% +$15.3K ﹤0.01% 4774
2023
Q3 		$68.4K Sell
11,309
-5,171
-31% -$42.4K ﹤0.01% 5006
2023
Q2 		$128K Buy
16,480
+14,600
+777% +$82.9K ﹤0.01% 4881
2023
Q1 		$10.7K Buy
1,880
+1,431
+319% +$7.48K ﹤0.01% 5842
2022
Q4 		$2.65K Buy
449
+5
+1% +$17 ﹤0.01% 5938
2022
Q3 		$2K Sell
444
-80
-15% -$320 ﹤0.01% 6175
2022
Q2 		$2K Sell
524
-177,803
-100% -$709K ﹤0.01% 6351
2022
Q1 		$953K Sell
178,327
-3,834
-2% -$34.5K ﹤0.01% 3934
2021
Q4 		$2.68M Sell
182,161
-1,026,631
-85% -$16M ﹤0.01% 3209
2021
Q3 		$25.3M Sell
1,208,792
-32,489
-3% -$659K 0.01% 1484
2021
Q2 		$22M Buy
1,241,281
+37,540
+3% +$823K ﹤0.01% 1604
2021
Q1 		$29.5M Buy
1,203,741
+349,935
+41% +$11.1M 0.01% 1371
2020
Q4 		$28.9M Buy
853,806
+229,870
+37% +$6.6M 0.01% 1300
2020
Q3 		$15.6M Buy
623,936
+52,975
+9% +$1.26M ﹤0.01% 1574
2020
Q2 		$19.3M Buy
+570,961
New +$18.2M 0.01% 1400

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wells Fargo's ORIC Position: Q2 2026 in Review

Wells Fargo increased its Oric Pharmaceuticals (ORIC) stake by 122% in Q2 2026, buying an estimated $434K and bringing the position to 87,009 shares worth $942K. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

Wells Fargo first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $29.5M in Q1 2021. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Wells Fargo held 87,009 shares of Oric Pharmaceuticals worth $942K as of Q2 2026.
  • Wells Fargo bought 47,901 Oric Pharmaceuticals shares in Q2 2026, an estimated $434K.
  • Oric Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4153 holding.
  • Wells Fargo first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Wells Fargo's Oric Pharmaceuticals position peaked at $29.5M in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.